Asia: Increase political engagement,
develop investment cases, reduce transmission through unsafe medical
procedures, maintain and expand HBV vaccine coverage and capitalise on cheap
generic access to greatly expand treatment.
Middle East and North Africa: Improve surveillance to reveal
burden of viral hepatitis, develop national elimination plans, improve HBV
birth-dose vaccine coverage and adult vaccination, reduce transmission through
unsafe medical procedures, increase treatment through access to cheap generics
and improve targeted screening to identify people in urgent need of HCV
Americas: Improve resourcing of
surveillance, focus on treatment and care for incarcerated populations, develop
non-specialist services outside large urban facilities, improve the procurement
of affordable medicines through mechanisms such as Pan American Health Organization.
European Union: Develop a regional strategy for
drug procurement, develop costed elimination plans, strengthen HCV screening,
harm reduction and treatment among the highest-risk groups, ensure access to
health services for migrants, promote decentralised care.
Sub-Saharan Africa: Improve HBV birth-dose vaccine
coverage and adult vaccination, promote universal maternal HBV screening,
reduce transmission through unsafe medical procedures, increase HBV treatment
through access to cheap generics, ensure access to high-quality nucleic acid
testing, develop education programmes around HBV and HCV to decrease public
stigma around viral hepatitis, mobilise community-based activist or support
groups to support viral hepatitis programmes.
Eastern Europe and Central Asia: Develop surveillance,
anti-discrimination policies, decriminalise drug possession, scale up harm
reduction that includes opioid substitution therapy, improve awareness of viral
hepatitis and cooperation between government and civil society, improve access
to low-cost quality generics through use of TRIPS (Trade Related Aspects of Intellectual Property Rights) flexibilities.